摘要
目的探讨马来酸曲美布汀联合谷维素治疗肠易激综合征的疗效及安全性。方法收集50例肠易激综合征患者资料,将患者完全随机分为观察组和对照组,各25例,观察组患者采用马来酸曲美布汀联合谷维素治疗,对照组患者采用马来酸曲美布汀治疗,比较两组患者的治疗效果。结果观察组患者治疗效果优于对照组,且不良反应低于对照组,差异均有统计学意义(均P<0.05)。结论马来酸曲美布汀联合谷维素治疗肠易激综合征可有效提高治疗效果,且安全性较高。
Objective To evaluate trimebutine maleate combined with oryzanol in treatment of irritable bowel syndrome efficacy and safety.Methods We selected 50 cases of patients with irritable bowel syndrome,the patients were randomly divided into observation group and control group,each 25 cases,observation combined with oryzanol treated with trimebutine maleate group of patients,the control group was treated with trimebutine maleate in the treatment of patients,treatment effects were compared between the two groups.Results Patients in the observation group treatment is better than the control group,and the adverse reaction is lower than that of the control group,the difference was statistically significant(P〈0.05).Conclusion Trimebutine maleate combined with oryzanol in treatment of irritable bowel syndrome can effectively improve the effect,and high safety.
出处
《中国药物经济学》
2015年第5期88-89,共2页
China Journal of Pharmaceutical Economics
关键词
马来酸曲美布汀
谷维素
肠易激综合征
疗效
Maleic acid trimebutine
Oryzanol
Irritable bowel syndrome
The curative effect